Video transcript
On Screen Text
AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in:
- individuals 60 years of age and older;
- individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.
Important Safety Information
- AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
- Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of AREXVY
Please see additional Important Safety Information at the end of this video and full Prescribing Information at the link above.
Audio
AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in:
- individuals 60 years of age and older;
- individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.
Important Safety Information
- AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
- Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of AREXVY
On Screen Text
Alix Schnibben, PharmD, BCACP, CTTS Director, Clinical Quality and Ambulatory Pharmacy Services, Gainesville, GA
Lower Third Text
Dr. Schnibben has been compensated by GSK for participation in this program
Audio
Hi. I'm Alix Schnibben. I have a background as a retail pharmacist. I worked several years as a market lead over health testing, immunization, and medication therapy management. And I am now an ambulatory care pharmacist, and a Director of Clinical Quality and Ambulatory Pharmacy Services at a health system in Northeast Georgia.
On Screen Text
How do I identify patients for RSV vaccination in the pharmacy setting?
Audio
So every day, we spend our lives as pharmacists, whether you're an ambulatory care pharmacist, a hospital-based pharmacist, or a retail pharmacist, really caring for our community.
Patients arrive at our pharmacies from multiple different avenues. They could be sick, they could be healthy. And we want to take that opportunity to close the care gap.
One thing we have in our toolbox, that I always think about, is vaccinations.
In this case, are they eligible to receive the RSV vaccination?
Lower Third Text
RSV=respiratory syncytial virus.
On Screen Text
AREXVY can lower the risk of lower respiratory tract disease associated with RSV in adults 60 years of age and older.1
Lower Third Text
RSV=respiratory syncytial virus.
Audio
With AREXVY, it's currently approved for patients who are 60 years of age and older, including those with certain comorbid conditions.1 So as a pharmacist, we know who those patients are.
Patients arrive to our pharmacy to pick up medications all the time.
This is our opportunity to counsel patients about vaccine care gaps.
If a patient is 60 years of age or older, they're a good patient for this.1,2 I'm going to take the opportunity to have that conversation.
Some of the things that I use to have a conversation with my patients who I identify are candidates for AREXVY, is I use the Vaccine Information Statement, or the VIS,2 and sit down with the patient, and use a highlighter, and really highlight the pertinent information.
Because I want them to understand that AREXVY is for the prevention of lower respiratory tract disease associated with RSV.1
And a lot of patients, right now, are asking about AREXVY.
I spend a lot of time going over what it is, what their risk is, and why we're talking about it now. It's really important for them to understand the disease process that we're just trying to prevent for the patient.
Lower Third Text
RSV=respiratory syncytial virus; VIS=Vaccine Information Statement.
On Screen Text
Important Safety Information (continued)
- Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
- Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY
- In adults 60 years of age and older, the most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
- In adults 50 through 59 years of age, the most commonly reported adverse reactions (≥10%) were injection site pain (75.8%), fatigue (39.8%), myalgia (35.6%), headache (31.7%), arthralgia (23.4%), erythema (13.2%), and swelling (10.4%)
- There are no data on the use of AREXVY in pregnant or breastfeeding individuals. AREXVY is not approved for use in persons <50 years of age
- Vaccination with AREXVY may not result in protection of all vaccine recipients
Please see full Prescribing Information at the link above.
Audio
Important Safety Information (continued)
- Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
- Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY
- In adults 60 years of age and older, the most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
- In adults 50 through 59 years of age, the most commonly reported adverse reactions (≥10%) were injection site pain (75.8%), fatigue (39.8%), myalgia (35.6%), headache (31.7%), arthralgia (23.4%), erythema (13.2%), and swelling (10.4%)
- There are no data on the use of AREXVY in pregnant or breastfeeding individuals. AREXVY is not approved for use in persons <50 years of age
- Vaccination with AREXVY may not result in protection of all vaccine recipients
Please see full Prescribing Information at the link above.
On Screen Text
Thank you for watching.
To learn more about AREXVY, visit
AREXVYhcp.com
References: 1. Prescribing Information for AREXVY. 2. Vaccination Information Statement. RSV (respiratory syncytial virus) vaccine: what you need to know. Centers for Disease Control and Prevention. Accessed February 16, 2024. http://www.cdc.gov/vaccines/hcp/vis/vis-statements/rev.html
Lower Third Text
AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)
GSK
Intended for US healthcare professionals only.
Trademarks are owned by or licensed to the GSK group of companies.
©2024 GSK or licensor.
PMUS-RSAVID240025 August 2024
Produced in USA.
close